阿地溴铵对高危慢性阻塞性肺疾病患者主要心血管事件和急性加重的影响:ASCENT-COPD随机临床试验
这项多中心随机双盲安慰剂对照研究在北美522个中心纳入3630例中度至极重度COPD且伴心血管病史或至少2项动脉粥样硬化血栓形成危险因素的患者,随访至发生至少122例主要不良心血管事件(MACE)。阿地溴铵400μg每日两次在3年内MACE风险方面非劣于安慰剂,且第一年中度至重度急性加重年发生率显著降低。
要点
- 阿地溴铵组MACE发生69例(3.9%),安慰剂组76例(4.2%),HR 0.89(单侧97.5%CI 0-1.23),达到非劣效。
- 扩展MACE定义事件阿地溴铵组168例(9.4%)vs 安慰剂组160例(8.9%),HR 1.03(单侧97.5%CI 0-1.28)。
- 阿地溴铵较安慰剂显著降低第一年中度至重度急性加重年发生率(0.44 vs 0.57,率比0.78,P<.001)。
核心结论
- 在COPD且心血管风险增高的患者中,阿地溴铵在3年内MACE风险方面非劣于安慰剂。
- 第一年中度至重度COPD急性加重率降低。
研究设计与样本
- 多中心、随机、安慰剂对照、双盲、平行设计研究,在北美522个中心开展。
- 共3630例中度至极重度COPD且伴心血管病史或至少2项动脉粥样硬化血栓形成危险因素的患者被随机分配,随访至发生至少122例MACE,最长3年。
- 患者随机接受阿地溴铵(n=1812)或安慰剂(n=1818)干粉吸入,每日两次,最长3年。
- 首例患者入组于2013年10月16日,末例于2016年8月22日;末例患者完成随访于2017年9月21日。
- 分析人群共3589例,平均年龄67.2岁,男性58.7%,2537例(70.7%)完成研究。
主要发现
- MACE:阿地溴铵组69例(3.9%)vs 安慰剂组76例(4.2%),HR 0.89(单侧97.5%CI 0-1.23)。
- 扩展MACE定义事件:阿地溴铵组168例(9.4%)vs 安慰剂组160例(8.9%),HR 1.03(单侧97.5%CI 0-1.28)。
- 第一年中度至重度急性加重年发生率:阿地溴铵组0.44 vs 安慰剂组0.57,率比0.78(双侧95%CI 0.68-0.89),P<.001。
- 需住院的急性加重年发生率:阿地溴铵组0.07 vs 安慰剂组0.10,率比0.65(双侧95%CI 0.48-0.89),P=.006。
- 最常见不良事件:肺炎(阿地溴铵组109例事件[6.1%] vs 安慰剂组105例事件[5.8%])、尿路感染(93例事件[5.2%] vs 89例事件[5.0%])、上呼吸道感染(86例事件[4.8%] vs 101例事件[5.6%])。
关键数值与推荐
- 主要安全性终点为至首次MACE时间,非劣效界值为HR单侧97.5%CI上限1.8。
- 主要疗效终点为治疗第一年COPD急性加重年发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease (COPD). OBJECTIVE: To determine the cardiovascular safety (noninferiority) and efficacy (superiority) of aclidinium bromide, 400 μg twice daily, in patients with COPD and cardiovascular disease or risk factors. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, placebo-controlled, double-blind, parallel-design study conducted at 522 sites in North America. A total of 3630 patients with moderate to very severe COPD and either a history of cardiovascular disease or at least 2 atherothrombotic risk factors were randomized; follow-up occurred for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred. The first patient was enrolled on October 16, 2013 and the last on August 22, 2016. The final patient completed follow-up on September 21, 2017. INTERVENTIONS: Patients were randomized to receive aclidinium (n = 1812) or placebo (n = 1818) by dry-powder inhaler, twice daily for up to 3 years. MAIN OUTCOMES AND MEASURES: The primary safety end point was time to first MACE over up to 3 years (hazard ratio [HR] 1-sided 97.5% CI noninferiority margin = 1.8). The primary efficacy end point was the annual COPD exacerbation rate during the first year of treatment. Secondary outcomes included an expanded MACE definition (time to first MACE or serious cardiovascular event of interest) and annual rate of exacerbations requiring hospitalization. RESULTS: Among 3589 patients analyzed (mean age, 67.2 years; 58.7% male), 2537 (70.7%) completed the study. Of these, 69 (3.9%) aclidinium and 76 (4.2%) placebo patients had a MACE (HR, 0.89; 1-sided 97.5% CI, 0-1.23); the expanded MACE definition included 168 (9.4%) aclidinium vs 160 (8.9%) placebo patients with events (HR, 1.03; 1-sided 97.5% CI, 0-1.28). Annual moderate to severe exacerbation rates (aclidinium, 0.44; placebo, 0.57; rate ratio, 0.78; 2-sided 95% CI, 0.68-0.89; P < .001) and rate of exacerbations requiring hospitalization (aclidinium, 0.07; placebo, 0.10; rate ratio, 0.65; 2-sided 95% CI, 0.48-0.89; P = .006) decreased significantly with aclidinium vs placebo. The most common adverse events were pneumonia (aclidinium, 109 events [6.1%]; placebo, 105 events [5.8%]), urinary tract infection (aclidinium, 93 events [5.2%]; placebo, 89 events [5.0%]), and upper respiratory tract infection (aclidinium, 86 events [4.8%]; placebo, 101 events [5.6%]). CONCLUSIONS AND RELEVANCE: Among patients with COPD and increased cardiovascular risk, aclidinium was noninferior to placebo for risk of MACE over 3 years. The rate of moderate to severe COPD exacerbations was reduced over the first year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01966107.
引用
- Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA. 2019. PMID: 31063575. doi:10.1001/jama.2019.4973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。